AI-based blood test outperforms ultrasound in early liver cancer detection

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Helio Genomics, an AI-driven healthcare company specializing in diagnostics technology and test development for cancer detection, has released results from its latest clinical trial demonstrating the superior performance of their HelioLiver Dx test compared to ultrasound. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Artificial Intelligence can improve breast cancer detection and reduce workload on physicians, according to a new study featuring over 461,000 women. The research published in the journal Nature Medicine looked at integrating an AI tool as part of a national screening program for women without symptoms of breast cancer in Germany.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login